Key result
Elevated atherogenic index of plasma is linked to ~68% higher risk of cognitive impairment.
Why the study?
The atherogenic index of plasma is a novel biomarker for dyslipidemia linked to various diseases, but its relationship with cognitive impairment in middle-aged and older adults required exploration.
Does an elevated atherogenic index of plasma increase the risk of cognitive impairment in middle-aged and older adults?
Cohort (n=7,918)
Yes
Does an elevated atherogenic index of plasma increase the risk of cognitive impairment in middle-aged and older adults?
Elevated atherogenic index of plasma is independently associated with an increased risk of cognitive impairment in middle-aged and older adults, suggesting a potential role for lipid management in preserving cognitive health.
Answers are grounded in this paper and cite their sources.
May flag higher cognitive risk via lipid profiling; leaves open whether AIP modification alters outcomes.
Background The atherogenic index of plasma (AIP) has been proposed as a novel biomarker predictor for dyslipidemia and has been linked to various diseases. In this study, we explored the relationship between AIP levels and cognitive impairment in a middle-aged and older population. Methods This study utilized data from the China Health and Retirement Longitudinal Study (CHARLS) for 7,918 individuals aged 45 and older. The AIP was calculated as the logarithmic ratio of triglycerides to high-density lipoprotein cholesterol. To assess the relationship between the AIP and cognitive impairment, logistic regression models were employed, while restricted cubic spline analysis was conducted to explore potential non-linear associations between AIP levels and cognitive impairment. Results The study participants had a mean age of 58.4 ± 8.8 years, and 49.1% were female. From 2011 to 2018, 2,911 participants (36.8%) developed cognitive impairment. After adjusting for potential confounders, the AIP was found to be significantly associated with cognitive impairment. In particular, participants in the higher AIP quartiles (Q2: odds ratio [OR]: 1.45, 95% confidence interval [CI]: 1.24–1.69, P < 0.001, Q3: OR: 1.63, 95% CI: 1.40–1.91, P < 0.001, and Q4: OR: 1.68, 95% CI: 1.43–1.98, P < 0.001) showed an increased risk of cognitive impairment compared to those in the lowest quartile (Q1). Additionally, a non-linear relationship was observed between AIP levels and cognitive impairment risk (P for nonlinear < 0.001). Conclusion The study finds that elevated AIP levels are linked to an increased risk of cognitive impairment in middle-aged and older adults, suggesting that managing dyslipidemia could help reduce this risk.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2025) conducted a cohort in Cognitive impairment (n=7,918). Atherogenic index of plasma (AIP) vs. Lowest AIP quartile (Q1) was evaluated on Cognitive impairment (OR 1.68, 95% CI 1.43-1.98, p=<0.001). Elevated atherogenic index of plasma (highest quartile) was associated with a 68% increased risk of cognitive impairment compared to the lowest quartile (OR 1.68) in middle-aged and older adults.
Synapse has enriched 10 related papers. Consider them for comparative context: